The primary standard treatment against advanced prostate cancer was androgen-deprivation therapy, either surgical castration or LHRH analogue, but in spite of castration levels of testosterone, certain cells can adapt and resume proliferation mostly with an associated increase in prostate-specific antigen, resulting in castration-resistant prostate cancer (CRPC) [7,8,9]. The gene discussed is KLK3; the disease is prostate carcinoma.